Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Chi-Med to Announce Half-Year Financial Results

29 Jun 2018 07:00

RNS Number : 9064S
Hutchison China Meditech Limited
29 June 2018
 

 

Chi-Med to Announce 2018 Half-Year Financial Results

 

London: Friday, June 29, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST).

 

An analyst presentation will be held at 9:00 am BST (4:00 pm Hong Kong Time) on the same day at Citigate Dewe Rogerson, 3 London Wall Buildings, London, EC2M 5SY, UK, which will be webcast via the company website at www.chi-med.com/investors/event-information/. The presentation will be available to download before the analyst presentation begins.

 

For North America based analysts and investors, Chi-Med will also host a conference call with Q&A at 9:00 am Eastern Daylight Time (2:00 pm BST).

 

Details of the analyst presentation and conference call dial-in will be provided in the financial results announcement. A replay will also be available on the website shortly after each event.

 

 

About Chi-Med

 

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

 

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

 

 

CONTACTS

 

Investor Enquiries

Mark Lee, Senior Vice President,Corporate Finance & Development

+852 2121 8200

U.K. & International Media Enquiries

Anthony Carlisle,Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)anthony.carlisle@cdrconsultancy.co.uk

U.S. Based Media Enquiries

Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)bmiles@troutgroup.com

Susan Duffy, Solebury Trout

+1 (917) 499 8887 (Mobile)sduffy@troutgroup.com

Investor Relations

Xuan Yang, Solebury Trout

+1 (415) 971 9412 (Mobile)xyang@troutgroup.com

David Dible,Citigate Dewe Rogerson

+44 7967 566 919 (Mobile)david.dible@citigatedewerogerson.com

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts

+44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORFMGZVLRKGRZG

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.